Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN…
SUNNYVALE, CA—Oct. 10, 2024—PRNewswire—CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the pricing…
Medical-device companies are raising big venture rounds to fortify their business and position themselves for a strong public offering or sale Venture investors are writing large checks to maturing medical-device…
Financing Fuels the Company’s Hypergrowth to Make Elevated Care Accessible to More Patients. Petrovic’s Appointment Positions Imperative Care for Long Term Success and Scale. CAMPBELL, CA—(BUSINESS WIRE)—Imperative Care, Inc., a…
Kestra Medical Technologies, Inc. announced today an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its…
Fidelity Management & Research Company Leads Financing; Nexus Neurotech Ventures and Ally Bridge Group Co-Lead Robust Investor Syndicate. FOR IMMEDIATE RELEASE: HAIFA, ISRAEL AND MIAMI, FL—Insightec, a global healthcare company…
– Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis, and ENV-501, a next-generation HER3-targeted antibody-drug conjugate, for solid tumors –…
Company Announcement • Genmab to acquire ProfoundBio for USD 1.8 billion in cash • Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S),…
NEW YORK—(BUSINESS WIRE)—Ally Bridge Group (“ABG”), a leading global healthcare investment firm focused on high-impact life science innovation, today announced several key promotions within its investment team and a new…
– Proceeds to support development of ProfoundBio’s differentiated clinical-stage ADC pipeline, including the planned pivotal trial of rinatabart sesutecan (Rina-S) – Financing led by Ally Bridge Group, bolstered by contributions…
